The national priority Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) trial is open at UHS and recruiting patients from ICU.

REMAP-CAP, led in Southampton by PI Dr Ahilanadan Dushianthan, is a multi-centre international adaptive platform trial of critically ill patients with community acquired pneumonia, including COVID-19.

It has multiple domains to evaluate multiple interventions simultaneously, including antivirals and immunomodulators, and will also evaluate potential interactions. 

You can find out more about the study at

Please email for more information.